IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.599
AS - Asia 9.926
EU - Europa 7.459
SA - Sud America 1.327
AF - Africa 506
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 30.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.351
SG - Singapore 3.536
CN - Cina 2.899
VN - Vietnam 1.585
IT - Italia 1.375
FI - Finlandia 1.151
IE - Irlanda 1.136
BR - Brasile 1.057
SE - Svezia 990
DE - Germania 796
HK - Hong Kong 701
UA - Ucraina 546
FR - Francia 357
ZA - Sudafrica 326
NL - Olanda 298
TR - Turchia 293
GB - Regno Unito 210
IN - India 204
RU - Federazione Russa 160
CA - Canada 158
AR - Argentina 108
AT - Austria 98
BD - Bangladesh 87
BE - Belgio 87
KR - Corea 77
CI - Costa d'Avorio 72
JP - Giappone 69
MX - Messico 59
PL - Polonia 59
IQ - Iraq 58
ID - Indonesia 52
EC - Ecuador 46
PK - Pakistan 44
ES - Italia 43
CO - Colombia 38
CZ - Repubblica Ceca 38
PH - Filippine 38
TH - Thailandia 35
VE - Venezuela 30
IR - Iran 24
LT - Lituania 24
MA - Marocco 24
UZ - Uzbekistan 24
EG - Egitto 22
JO - Giordania 21
SA - Arabia Saudita 20
TN - Tunisia 16
TW - Taiwan 16
KE - Kenya 15
PS - Palestinian Territory 15
AE - Emirati Arabi Uniti 13
EE - Estonia 12
PY - Paraguay 12
AZ - Azerbaigian 11
IL - Israele 11
MY - Malesia 11
KZ - Kazakistan 10
PE - Perù 10
AL - Albania 9
CL - Cile 9
DZ - Algeria 9
HU - Ungheria 9
LB - Libano 9
NP - Nepal 9
OM - Oman 9
RO - Romania 9
UY - Uruguay 9
JM - Giamaica 8
AU - Australia 7
BO - Bolivia 7
LU - Lussemburgo 7
QA - Qatar 7
SY - Repubblica araba siriana 7
CH - Svizzera 6
ET - Etiopia 6
GE - Georgia 6
KG - Kirghizistan 6
MD - Moldavia 6
PA - Panama 5
PT - Portogallo 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AM - Armenia 3
BG - Bulgaria 3
BW - Botswana 3
EU - Europa 3
GT - Guatemala 3
HR - Croazia 3
LK - Sri Lanka 3
NO - Norvegia 3
SI - Slovenia 3
SN - Senegal 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
Totale 30.800
Salva come PNG Salva come JPEG
Città #
Singapore 1.823
Ashburn 1.272
Dublin 1.133
Chandler 1.092
Dallas 1.011
San Jose 896
Santa Clara 677
Beijing 665
Hong Kong 653
Jacksonville 613
Ann Arbor 597
Ho Chi Minh City 471
Parma 462
Dearborn 447
Boardman 363
Hanoi 356
Johannesburg 311
New York 268
Nanjing 264
Los Angeles 258
Izmir 244
Shanghai 232
Princeton 210
Munich 208
Lauterbourg 206
San Mateo 178
Hefei 165
Wilmington 138
Bremen 128
Helsinki 115
São Paulo 108
Chicago 104
Milan 101
Nanchang 98
Kunming 93
Shenyang 92
Toronto 90
Hebei 85
Moscow 83
Vienna 83
Jinan 82
Buffalo 80
Haiphong 74
Abidjan 72
Woodbridge 72
Brussels 70
Council Bluffs 64
Frankfurt am Main 64
Tianjin 64
Da Nang 62
Columbus 58
Des Moines 57
Seattle 54
Seoul 53
Guangzhou 52
Houston 50
Marseille 50
Tokyo 50
Bologna 49
Changsha 49
Turku 49
The Dalles 48
Jiaxing 46
Warsaw 41
London 40
Pune 40
Brooklyn 38
Modena 36
Amsterdam 35
Norwalk 35
Rio de Janeiro 35
Stockholm 33
Düsseldorf 32
Jakarta 32
Rome 32
Denver 31
Belo Horizonte 26
Brasília 25
Hangzhou 25
Manchester 25
Montreal 25
Orem 25
Biên Hòa 24
Phoenix 24
Redmond 24
Reggio Emilia 24
San Francisco 24
Augusta 23
Chennai 23
Fremont 23
Tashkent 23
Zhengzhou 23
Hải Dương 22
Atlanta 21
Baghdad 21
Boston 21
New Delhi 21
Dhaka 20
Leawood 20
Poplar 20
Totale 18.774
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 273
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 242
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 221
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 209
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 206
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 205
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 204
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 204
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 191
Characterization of gefitinib uptake in NSCLC cell lines 189
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 181
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 181
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 180
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 179
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 179
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 177
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 177
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
5-benzylidene-hydantoins as new inhibitors of cell proliferation 176
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 175
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 170
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 169
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 168
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 166
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 164
An original application of plasma expanders: heart-lung preservation. 164
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 162
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 160
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 158
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 156
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 156
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 156
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 155
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 154
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 154
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 153
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 150
Adaptive cellular response to osmotic stress in pig articular chondrocytes 150
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 150
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 149
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 148
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 147
SiO2/SiC core-shell nanowires for nanomedicine applications 147
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 146
New MDR1 inhibitors for overcoming multidrug resistance 146
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Left lung allotransplantation in the rabbit. An experimental model for assessment of lung preservation 145
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 144
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 144
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 144
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 144
Mannich base derivatives as novel EGFR irreversible inhibitors 144
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 144
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 144
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 144
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 144
Induction of betaine/gammabutyric acid transport activity in chondrocytes exposed to hypertonicity 143
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 143
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
SiO2/SiC core-shell nanowires for nanomedicine applications 141
Totale 17.193
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021428 0 0 0 0 0 0 0 0 0 55 312 61
2021/20221.057 49 33 48 65 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.843 88 141 59 50 151 456 133 141 65 96 160 303
2024/20255.752 190 298 368 406 555 618 313 236 778 500 510 980
2025/202611.306 1.111 1.163 1.531 1.111 1.610 662 1.300 377 1.658 783 0 0
Totale 31.147